Pasithea Therapeutics (KTTA) Change in Accured Expenses (2021 - 2026)
Pasithea Therapeutics recorded quarterly Change in Accured Expenses of $358381.0 in Q1 2026, up 273.38% quarter-over-quarter from -$206697.0 in Q4 2025, and up 73.93% year-over-year from $206054.0 in Q1 2025.
Pasithea Therapeutics' Change in Accured Expenses history runs 6 years deep, the most recent figure standing at $358381.0 for Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 73.93% year-over-year to $358381.0; the TTM figure through Mar 2026 stood at $163560.0 (up 114.76% YoY), while the FY2025 annual figure was $11233.0, up 100.78% from the prior year.
- Change in Accured Expenses came in at $358381.0 for Q1 2026 at Pasithea Therapeutics, up from -$206697.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $682903.0 in Q4 2023 to a low of -$1.0 million in Q2 2024.
- A 5-year average of $44344.2 and a median of $30384.0 in 2022 frame the typical range for Change in Accured Expenses.
- Across the five-year window, Change in Accured Expenses jumped 1437.84% in 2023 and slumped 1572.63% in 2024, its largest moves.
- Pasithea Therapeutics' Change in Accured Expenses stood at $280153.0 in 2022, then surged by 143.76% to $682903.0 in 2023, then decreased by 29.22% to $483373.0 in 2024, then tumbled by 142.76% to -$206697.0 in 2025, then soared by 273.38% to $358381.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $358381.0, -$206697.0, and -$243700.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - | 358,381.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 358,381.00 |
| Mar 31, 2026 | 358,381.00 |
| Dec 31, 2025 | -206,697.00 |
| Dec 31, 2025 | -206,697.00 |
| Sep 30, 2025 | -243,700.00 |
| Sep 30, 2025 | -243,700.00 |
| Jun 30, 2025 | 255,576.00 |
| Jun 30, 2025 | 255,576.00 |
| Mar 31, 2025 | 206,054.00 |
| Mar 31, 2025 | 206,054.00 |
| Dec 31, 2024 | 483,373.00 |
| Dec 31, 2024 | 483,373.00 |
| Sep 30, 2024 | -758,354.00 |
| Sep 30, 2024 | -758,354.00 |
| Jun 30, 2024 | -1.04 Mn |
| Jun 30, 2024 | -1.04 Mn |
| Mar 31, 2024 | -118,369.00 |
| Mar 31, 2024 | -118,369.00 |
| Dec 31, 2023 | 682,903.00 |
| Dec 31, 2023 | 682,903.00 |
| Sep 30, 2023 | -45,339.00 |
| Sep 30, 2023 | -45,339.00 |
| Jun 30, 2023 | 467,258.00 |
| Jun 30, 2023 | 467,258.00 |
| Mar 31, 2023 | -33,855.00 |
| Mar 31, 2023 | -33,855.00 |
| Dec 31, 2022 | 280,153.00 |
| Dec 31, 2022 | 280,153.00 |
| Sep 30, 2022 | 405,669.00 |
| Sep 30, 2022 | 405,669.00 |
| Jun 30, 2022 | 30,384.00 |
| Jun 30, 2022 | 30,384.00 |
| Mar 31, 2022 | 29,553.00 |
| Mar 31, 2022 | 29,553.00 |
| Dec 31, 2021 | -80,816.00 |
| Dec 31, 2021 | -80,816.00 |
| Sep 30, 2021 | 73,415.00 |
| Sep 30, 2021 | 73,415.00 |
| Jun 30, 2021 | 215,228.00 |
| Jun 30, 2021 | 215,228.00 |
| Mar 31, 2021 | 232,850.00 |
| Mar 31, 2021 | 232,850.00 |